Showing 1 to 10 of 14 Clinical Trials
|
CLINICAL TRIAL Trial No ClinicalTrials.gov ID |
Principal Investigator
Coordinator |
||
|---|---|---|---|
|
A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)
ME13 NCT02821013  Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Melanoma |
Dr. Catalin Mihalcioiu Ann Bartulovic 514-934-1934 poste 35033 |
|
Melanoma Margins Trial-II - A Phase III, Multi-centre Randomised Controlled Trial Investigating 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
ME15 NCT03860883 Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Melanoma |
Dr. Cindy Boulanger-Gobeil Maryse Gingras 418-691-5781 |
|
A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition
MONETTE NCT05061134 Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Melanoma |
Dr. Joël Claveau Véronique Jobin 418-525-4444 poste 15780 |
|
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma
RELATIVITY-127 (CA224-127) NCT05625399 Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Melanoma |
Dr. Félix Couture Maryse Gingras 418-691-5781 |
|
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma
V940-001 NCT05933577 Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Melanoma |
Dr. Joël Claveau Mélanie Bradley 418-525-4444 poste 12950 |
|
Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)
MIMic NCT03772899 Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Melanoma |
Dr. Wilson Miller Sarah Kassis 514-340-8222 poste 22075 |
|
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies After Progression on Prior PD-1 Inhibitor Treatment
SGN35-033 (KEYNOTE B81) NCT04609566 Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Head and Neck Melanoma Non Small Cells - Lung |
Dr. Wilson Miller Daria Krutauz 514-340-8222 poste 24301 Rim Hojeij 514-340-8222 poste 26187 |
|
Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
BR-2021-CamuCamu NCT05303493 Recruiting
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Melanoma Non Small Cells - Lung |
Dr. Nathalie Daaboul Marilyn Tessier 450-466-5000 poste 7691 |
|
A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy
ARTISTRY-6 NCT04830124 Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Melanoma |
Dr. Rahima Jamal Samantha Gennevois 514-890-800 poste 31523 |
|
Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
BR-2021-CamuCamu NCT05303493 Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Melanoma Non Small Cells - Lung |
Dr. Bertrand Routy Wiam Belkaid 514-890-8000 |
Groupe d'étude en oncologie du Québec